DOCSLIB.ORG

ODWB 16 0.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ODWB 16 0.Pdf PACIFIC UNIVERSITY COLLEGE OF OPTOMETRY 2016 VICTORIA CONFERENCE July 21 to 24, 2016 Delta Victoria Ocean Point Victoria, B.C. CANADA COPE EVENT #111397 Date Speaker Title COPE Verification Thursday, Kathleen Elliott, Pediatrics/Geriatrics – Take 42824 July 21, OD Your Pick (2 hrs) 2 hours 2016 GO Implications of Selected Corneal Jeffrey Urness, 49516 2 hours Conditions on Refractive Surgery OD (2 hrs) AS Therapeutic Environment, Diet and Amber Giannoni, Supplements: What Role Do 40852 1 hour OD They Play in Dry Eye Disease? (1 hr) AS Therapeutic Friday, Amber Giannoni, Dry Eye and Systemic Disease 40851 2 hours July 22 OD (2 hrs) SD Therapeutic 49515 Kathleen Elliott, The ABC’s of Pediatric Eye Care 1 hour OD (1 hr) FV John McGreal, New Ideas in Glaucoma 43612 2 hours OD Management (2 hrs) GL Therapeutic Total hours offered: 10 Total hours earned: Name License # Mailing Address ______ Please retain a copy of this stamped form as verification of hours earned. Please be advised that your individual state board makes the final determination of applicable hours. For more information, contact Pacific University College of Optometry, 2043 College Way . Forest Grove, OR 97116 . 503-352-2202 1 of 193 2 of 193 PACIFIC UNIVERSITY COLLEGE OF OPTOMETRY 2016 VICTORIA CONFERENCE July 21 to 24, 2016 Delta Victoria Ocean Point Victoria, B.C. CANADA COPE EVENT #111397 Date Speaker Title COPE Verification Saturday, John McGreal, The Latest Trends in 43497 2 hours July23 OD Contemporary Medicine (2 hrs) PH Therapeutic Non-Surgical Radiofrequency Kathleen Elliott, 46927 2 hours Periocular Soft Tissue OD Rejuvenation (2 hrs) AS Therapeutic 42998 John McGreal, New Tools for the Tool Box 1 hour OD (1 hr) GO Sunday, Jeffrey Urness, 49517 1 hour Bacterial Corneal Ulcers (1 hr) July 24 OD AS Therapeutic 49514 Kathleen Elliott, Pediatric Case Reports: The 1 hour OD Good, Bad and Ugly (1 hr) FV 43552 Amber Giannoni, Setting Up a Dry Eye Practice 1 hour OD (1 hr) PM Jeffrey Urness, Corneal Transplantation Front 40409 2 hours OD to Back, Side to Side. PO Therapeutic Total hours offered: 10 Total hours earned: Name License # Mailing Address ______ Please retain a copy of this stamped form as verification of hours earned. Please be advised that your individual state board makes the final determination of applicable hours. For more information, contact Pacific University College of Optometry 2043 College Way . Forest Grove, OR 97116 . 503-352-2202 3 of 193 4 of 193 2016 Victoria Conference ‐ July 21 to 24 Wed Thursday 7/21 Friday 7/22 Saturday 7/23 Sunday 7/24 COPE ID: 49517 AS Bacterial Corneal Ulcers Jeffrey Urness COPE ID: 43497-PH COPE ID: 42824-GO COPE ID: 40851-SD 8:00 am to 9:00 am The Latest Trends in Pediatrics/Geriatrics-Take Your Dry Eye and Systemic Disease Contemporary Medicine Pages 142 - 153 Pick Amber Giannoni John McGreal Kathleen Elliott 8:00 am to 10:00 am 8:00 am to 10:00 pm 8:00 am to 10:00 am COPE ID: 49514 FV Pediatric Case Reports: the Good, Bad, and Ugly pages 39 - 68 Pages 91 - 112 pages 7 - 10 Kathleen Elliott 9:00 am to 10:00 am Pages 154 - 156 COPE ID 49515 FV COPE: 43552 PM The ABCs of Pediatric Eye Care COPE ID: 46927 AS Setting Up a Dry Eye Practice Kathleen Elliott Non-Surgical Radiofrequency Amber Giannoni COPE ID: 36382-AS 10:00 am to 11:00 am Periocular Soft Tissue 10:00 am to 11:00 am Implication of Selected Corneal Rejuvenation Conditions on Refractive pages 69 - 73 Pages 157 - 174 Kathleen Elliott Surgery 10:00 am to Noon Jeffrey Urness 10:00 am to Noon pages 113 - 125 pages 11 - 23 COPE ID: 43612-GL COPE ID: 40409-PO New Ideas In Glaucoma Corneal Transplantation Front to Management (2) Back Side to Side John Mcgreal Jeffrey Urness 11:00 am to 1:00 pm ARRIVAL RECEPTION COPE ID: 40852-AS COPE ID: 42998-GO 11:00 am to 1:00 pm Arbutus Foyer Environment, Diet and Supplement New Tools For The Tool Box 6:00 pm to 7:00 pm Pages 74 - 90 Amber Giannoni John McGreal pages 175 - 190 Noon to 1:00 pm 12:00 to 1:00 Pages 24 - 38 Pages 126 - 141 5 of 193 Amber Gaume Giannoni, OD, FAAO Jeff Urness, OD, FAAO, ABO Clinical Associate Professor Spokane, Washington University of Houston College of Dr. Urness is a graduate of Pacific University Optometry (UHCO) College of Optometry. He completed a Dr. Gaume Giannoni earned her optometry residency in Hospital Based Optometry at degree from UHCO and completed a Post- Northeastern State University College of Doctoral Fellowship in Cornea and Contact Optometry. Dr. Urness has served as a Lens Research with the Texas Eye Research and Technology Center consulting optometric physician in SE the following year. She is a Diplomate of the American Board of Washington for twenty years. Working in one of the few corneal Optometry, a Fellow of the American Academy of Optometry and is services in eastern Washington, Dr. Urness has developed an certified in Texas as an Optometric Glaucoma Specialist. She is on interest in and an affinity for management of patients with corneal the Editorial Board for Advanced Ocular Care and is a journal disease and corneal transplants. He is also an adjunct clinic reviewer for Optometry and Optometry and Vision Science. Dr. professor for Pacific University’s College of Optometry providing Gaume Giannoni writes a recurrent dry eye column in Contact Lens education to optometry students, residents and practicing Spectrum and is also a contributing editor for Ocular Surface News optometric physicians. Dr. Urness presently serves on the and is the Founding Director of the Dry Eye Center at the University optometric staff at the Manns -Granstaff VA Medical Center in Eye Institute where she sees specialty dry eye patients. Spokane Washington. Kathleen Foster Elliott, OD, Dipl.ABO Elaine Pedersen, B.Comm., CHRP Optometric Director Optometric Services Inc. His Vision for Children Clinic Ms. Pedersen is the National Training Coordinator for Optometric Services Tulsa, Oklahoma Inc., Canada’s largest buying and multi- Dr. Elliott graduated with honors from NSUOCO. She completed a residency in Ocular service group for optometrists. An Disease Management and went on to accomplished speaker, Elaine has given complete a two year post graduate study program in Pediatrics over 300 seminars to optometrists, with pediatric ophthalmology in Tulsa, OK, where she now optometric assistants and opticians across Canada. She practices. She was clinical director at a cataract /refractive surgery holds a Masters of Arts in Leadership from Royal Roads co-management center from 1994-1998. Dr. Elliott also co-owned University and a Bachelor of Commerce, specializing in and operated a successful private practice and hospital based clinic marketing from the University of British Columbia. Ms. in rural Oklahoma from 1998-2010. Dr. Elliott was recently Pedersen is also a Certified Human Resources Professional appointed by Oklahoma's Governor as the first female doctor to and Myers-Briggs certified. serve on the Board of Examiners in Optometry, where she serves as Secretary-Treasurer. She is the former Co- Chair of the state Legislative Committee and was named the Oklahoma Legislative Carole Timpone, OD, FAAO, FNAP Physician of the year for 2012, and received the Oklahoma Associate Dean for Clinical Programs Optometrist of the Year Award for 2014. Pacific University College of Optometry Her areas of interest, research, and expertise John McGreal, OD include ocular disease, glaucoma and primary Missouri Eye Associates care optometry. Dr. Timpone served as the director of the Pacific St. Louis, Missouri University Vision Clinic in Portland for more than 15 years. Since 2013 she has served as the Associate Dean of Clinical Programs at Dr. McGreal is a graduate of Albright College Pacific University. and the Pennsylvania College of Optometry. He has lectured nationally and internationally for over 20 years on topics ranging from clinical CONFERENCE STAFF care to compliance/coding. He has been honored as 1998 Missouri Jeanne Oliver, Director of External Relations Optometrist of the Year and 2005 University of Missouri Educator Victoria Conference Director of the Year. He is currently director of the Missouri Eye Associates, [email protected] a medical-surgical consultation center in St. Louis. Dr. McGreal is adjunct faculty at the University of California, Berkeley School of Marti Fredericks Optometry, the Pennsylvania College of Optometry and the Dir. of Externships & Residency Management University of Missouri. [email protected] 6 of 193 7/5/2016 Geriatrics Pediatrics/Geriatrics- Take Your Pick! • Systemic , Biological, and Physiological Changes with Aging • Demographics,Over 30 Kathleen Foster Elliott, OD, Dipl.,ABO; pts,Hospitalizations,Health Care George Foster, OD, and Les Walls,OD,MD Consumption, Geriatrics Geriatrics • Primary aging over 65,Organ system • Role of Health Care Providers,Basic reserve,Homeostatic Reserve Physiology aging changes • Secondary • Gaining a Background in Medical aging:Controllable/Reversible,Preventio Aspects of Geriatrics in regards to n keys, Systemic Disease 7 of 193 1 7/5/2016 Geriatrics Case reports • Theories on Etiology of aging,free • Skin,Orthopedic,Neurologic,Cardiovasc radical, ular,Auditory,Hypertension,Diabetes,Th Apoptosis,Genetic,Polygenic,Life yroid DZ,Immune Expectancy, System,Autoimmune,Cancer, Aging and the Eye Pediatrics • Medication Problems • Pediatric population and Optometric • AMD practices 8 of 193 2 7/5/2016 Case Reports Pediatrics • Eyelid Disorders,Diabetes, • Retinoblastoma,Retinal Hemorrhages , • The Impact of Geriatrics and Pediatrics
Load more

Recommended publications
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • 2Nd Quarter 2015 Earnings Call Presentation
    2nd Quarter 2015 Earnings Call Presentation July 14, 2015 1 Louise Mehrotra Vice President Investor Relations 2 Note on Forward-Looking Statements These presentations contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including global health care reforms; trends toward health
    [Show full text]
  • Page 1 of 27 MD Consult: Diabetes, Diet For: Comprehensive Version
    MD Consult: Diabetes, Diet for: Comprehensive Version: Patient Education Page 1 of 27 Boise Kidney and Hypertension 3525 East Louise Rd Ste 100 Meridian, ID 83642 208-846-8335 Diabetes diet Highlights Lifestyle Changes Essential for People at Risk for Diabetes Lifestyle interventions that include weight loss, dietary changes, and increased physical activity can definitely help prevent or delay the progression to diabetes among at-risk people, suggest several recent studies. Weight loss through diet and exercise is especially important for overweight people with pre-diabetes. Grain Fiber Important for Diabetes Prevention Eating whole-grain, fiber-rich, cereal foods may help reduce the risk of developing type 2 diabetes, indicates a 2007 study in the Archives of Internal Medicine. In the study, people who consumed the most fiber from grains and cereals had a 33% lower risk of developing diabetes than people with the lowest fiber intakes. The study also found an association between high magnesium intake and reduced diabetes risk. Although fruits and vegetables also contain fiber, they did not appear to affect diabetes risk. Low-Fat Dairy Products Incorporating low-fat dairy products (such as yogurt and milk) into a healthy diet may help reduce diabetes risk for women, suggests a study in Diabetes Care. Beware of Internet Dietary Supplement Scams In 2006, the FDA alerted consumers not to be misled by dietary supplements advertised on the Internet as treatments or cures for diabetes. These products have not been scientifically studied or approved. Low-Glycemic Index Diets Food low on the glycemic index -- such as whole grains, fruits, lentils, and soybeans -- can help promote weight loss and heart health.
    [Show full text]
  • Pursuit Resources Group Ltd First Floor, 4 Freeport Office Village, Century Drive
    Pursuit Resources Group Ltd First Floor, 4 Freeport Office Village, Century Drive, Braintree, Essex, CM77 8YG Telephone E-mail Website 01245 362500 [email protected] www.pursuitgroup.co.uk Candidate: 24870 2000 - 2003 South Bank University – • BA (Hons) Business Administration (2:1) 1998 - 2000 Westcliff High School Education: • A-levels: Biology, General Studies, Psychology 1993 - 1998 St. Bernard’s High School • GCSE’s: 10 A-C subjects, including English, Mathematics and Sciences Notice Period: 2 months Salary £38,000 NB: To give you an enhanced understanding of the candidate we have checked the validity of the information and left the CV in its original format. A media marketing manager with 10+ years’ experience delivering multiple cross-media campaigns for high profile brands. With track record of executing communication strategies and client objectives from conception to completion. Employment History: Media Account Director Nov 16 – present • Manage and coordinate a team to create and develop Nestlé’s Water and Nutrition divisions’ annual marketing strategy • in line with business objectives • Utilise a mix of media channels including above and below the line media (TV, OOH, print, radio, digital, social and • product placements) ensuring relevancy to the target audience • Keep up to date with new media innovations, changing media landscape and trends in the industry • Develop consumer and shopper insights to feed into overall media strategy to present back to senior business leaders • Strategise and implement
    [Show full text]
  • Challenges Facing the Branded Drug Industry
    CHAPTER 1 Challenges Facing the Branded Drug Industry In 2004, Capgemini conducted an industry - wide survey on pharmaceutical lifecycle management (LCM) ( “ Increasing the lifetime value of pharmaceuti- cal products, ” Capgemini Vision & Reality Research, 2004). They held a series of interviews with pharmaceutical industry executives, asking them how important LCM had been for their business in the past 5 years and how they expected its importance to change during the coming 5 years. As can be seen in Figure 1.1 , these executives felt that LCM had been important, but 90% predicted that its importance would grow during the 5 years following the publication of the report (2006 – 2010), with 60% expecting it to become much more important. Today, just after the time horizon of this prediction, we can look back and state that it has proven to be very accurate, with more and more attention paid to LCM in company statements, conferences, and industry reports. Why did these executives expect LCM to gain in importance, and why has their prediction proven to be correct? To set the scene for any discussion of LCM of pharmaceuticals, it is essential that one fully understands the challenges facing the branded drug industry. On the one hand, many of these factors are drivers of the increased interest in LCM; on the other hand, some of the factors actively discourage LCM and put into question the sustainability of certain LCM strategies that were suc- cessful in the past. As we see it, the main challenges are the following: • Depleted COPYRIGHTEDnew molecular entity (NME) pipelines/lower MATERIAL R & D effi ciency • Higher development costs • Safety concerns • Tougher environment for pricing, reimbursement, and listing Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand, First Edition.
    [Show full text]
  • Johnson & Johnson 1999 Third Quarter Sales Increased 17.9% Net
    Johnson & Johnson 1999 Third Quarter Sales Increased 17.9% Net Earnings Rose 14.4% EPS Rose 14.3 NEW BRUNSWICK, N.J., Oct. 19-- Johnson & Johnson (NYSE: JNJ) today announced sales of $6.7 billion and net earnings of $1.1 billion for the third quarter of 1999, increases of 17.9% and 14.4%, respectively, over 1998 third-quarter results. Diluted earnings per share for the third quarter were $.80, up 14.3% from the same period in 1998. The impact of the stronger dollar relative to foreign currencies decreased third-quarter sales by 1.3%. Domestic sales were up 24.1%, while international sales increased 10.7%, reflecting a negative currency impact of 2.9%. "We continue to achieve strong double-digit sales and earnings growth that reflects the strength and vitality of our businesses in all segments and almost all geographic areas," said Ralph S. Larsen, Chairman and Chief Executive Officer. "Of particular note is the impressive performance of our domestic pharmaceutical business." Worldwide pharmaceutical sales of $2.6 billion for the quarter increased 23.9% over the same period in 1998, including 35.7% growth in domestic sales and a 9.5% increase in international sales. International sales gains of 12.6% in local currency were offset by a negative currency impact of 3.1%. Sales growth reflects the strong performance of PROCRIT/EPREX, for the treatment of anemia; RISPERDAL, an antipsychotic medication; DURAGESIC, a transdermal patch for chronic pain; LEVAQUIN, an anti-infective; ULTRAM, an analgesic, and the oral contraceptive line of products. During the quarter, the company announced a $4.9 billion definitive stock-for-stock merger with Centocor, Inc., a leader in monoclonal antibody technology and acute vascular care and immunology products.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0180934A1 Ni Et Al
    US 2003O180934A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0180934A1 Ni et al. (43) Pub. Date: Sep. 25, 2003 (54) PLASMINOGEN-LIKE POLYNUCLEOTIDES, (60) Provisional application No. 60/158,044, filed on Oct. POLYPEPTIDES, AND ANTIBODIES 7, 1999. (75) Inventors: Jian Ni, Germantown, MD (US); Paul Publication Classification E. Young, Gaithersburg, MD (US); Steven M. Ruben, Olney, MD (US) 51) Int.nt. Cl.C.7 ............................ C12N 9/64; CO7H 21/04 C12P 21/02; C12N 5/06 Correspondence Address: (52) U.S. Cl. ..................... 435/226; 435/69.1; 435/320.1; HUMAN GENOME SCIENCES INC 435/325; 536/23.2 941O KEY WEST AVENUE ROCKVILLE, MD 20850 (73) Assignee: Human Genome Sciences, Inc., Rock (57) ABSTRACT ville, MD (US) (21) Appl. No.: 10/162,742 The present invention relates to novel human plasminogen like polypeptides and isolated nucleic acids containing the (22) Filed: Jun. 6, 2002 coding regions of the genes encoding Such polypeptides. Related U.S. Application Data Also provided are vectors, host cells, antibodies, and recom binant methods for producing human plasminogen-like (63) Continuation of application No. 09/832,197, filed on polypeptides. The invention further relates to diagnostic and Apr. 11, 2001, now abandoned, which is a continua therapeutic methods useful for diagnosing and treating dis tion-in-part of application No. PCT/US00/27253, orders related to these novel human plasminogen-like filed on Oct. 4, 2000. polypeptides. US 2003/0180934 A1 Sep. 25, 2003 PLASMINOGEN-LIKE POLYNUCLEOTIDES, the inactive Zymogen plasminogen, which is hydrolyzed to POLYPEPTIDES, AND ANTIBODIES yield the active two-chain Serine protease plasmin.
    [Show full text]
  • CLINICAL PROTOCOL HGS1006-C1112 Protocol Amendment: 02 Date: 09 February 2017 Eudract Number: 2011-005672-42
    CLINICAL PROTOCOL HGS1006-C1112 Protocol Amendment: 02 Date: 09 February 2017 EudraCT Number: 2011-005672-42 TITLE OF STUDY: A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52- Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE) STUDY SPONSOR: Human Genome Sciences, Inc. 9910 Belward Campus Drive Rockville, Maryland 20850 U.S.A. Confidentiality This document contains proprietary and confidential information of Human Genome Sciences, Inc. Acceptance of this document constitutes agreement by the recipient that no unpublished information contained herein will be published or disclosed without prior written approval from Human Genome Sciences, Inc., except that this document may be disclosed to study personnel under your supervision who need to know the contents for conducting the study and appropriate Institutional Review Boards/Independent Ethics Committees under the condition that they are requested to keep it confidential. The foregoing shall not apply to disclosure required by governmental regulations or laws, however, Human Genome Sciences, Inc. must be promptly informed of any such disclosure. 2014N199062_00 Human Genome Sciences, Inc. Confidential Page 2 Clinical Protocol HGS1006-C1112-02 Belimumab Revision Chronology for HGS1006-C1112 (BEL115471) Date Document* Global 21 November 2011 Original Global 20 June 2012 Amendment No 01 Local 02 February 2015 Local Amendment No 01 for France 2014N219219_00 Global 09 February 2017 Amendment No 02 2014N199062_00 *A Summary of Modifications document which provides a detailed list of changes for the amendment/addendum is available upon request. 2014N199062_00 Human Genome Sciences, Inc. Confidential Page 3 Clinical Protocol HGS1006-C1112-02 Belimumab Investigator Agreement I will provide copies of the protocol, any subsequent amendments and access to all information furnished by the sponsor to study personnel under my supervision.
    [Show full text]
  • 2014 Annual Report • 1 Management’S Discussion and Analysis of Results of Operations and Financial Condition
    ANNUAL REPORT 2014 MARCH 2015 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer I am often asked what led me to work in Perhaps there’s no better proof of that than the THERE IS health care and why I chose to spend most success Johnson & Johnson achieved in 2014. NO COMPANY of my career at Johnson & Johnson. From my We delivered solid financial results, with full-year BETTER first job at Janssen, the flagship company of 2014 sales of $74.3 billion and adjusted net POSITIONED our Pharmaceutical segment, to my current earnings of $17.1 billion†, while also continuing TO HELP MEET role as the company’s Chairman and CEO to make investments to accelerate growth for THESE URGENT 25 years later, the answer always begins the long term. NEEDS THAN with Our Credo. JOHNSON & And while I am pleased with our performance, JOHNSON A simple yet powerful document penned we know that we can never rest, because by General Robert Wood Johnson, the son of providing sustainable high-quality health care our founder and our company’s first Chairman, is one of our society’s greatest challenges. Our Credo outlines the Company’s commitments and responsibilities to the people and This is an unprecedented era in human history. communities we touch every day with our The historic aging rate of the world’s population, products and services. For more than 70 years along with a growing middle class around the now, it has served as the moral compass of world, brings dramatically greater demand for Johnson & Johnson – ensuring we never lose higher quality health care; and governments sight of our strong values and the important and health systems must manage this with needs of the many stakeholders we serve.
    [Show full text]
  • DUR Packet August 2011
    Drug Utilization Review Board Oklahoma Health Care Authority 2401 N.W. 23rd Street, Suite 1A Oklahoma City, Oklahoma 73107 Ponca Room Wednesday August 10, 2011 6:00 p.m. The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review Board Members FROM: Shellie Keast, Pharm.D., M.S. SUBJECT: Packet Contents for Board Meeting – August 10, 2011 DATE: August 4, 2011 NOTE: THE DUR BOARD WILL MEET AT 6:00 P.M. THE MEETING WILL BE HELD IN THE PONCA ROOM AT THE OKLAHOMA HEALTH CARE AUTHORITY OFFICES IN SHEPHERD MALL. (NORTH ENTRANCE) Enclosed are the following items related to the August meeting. Material is arranged in order of the Agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – See Appendix A. Update on DUR / MCAU Program – See Appendix B. Action Item –Vote to Prior Authorize Zuplenz® – See Appendix C. Action Item – Annual Review of Atypical Antipsychotics – See Appendix D. 30 Day Notice to Prior Authorize Diabetes Medications – See Appendix E. 30 Day Notice to Prior Authorize Berinert®, Cinryze®, and Kalbitor® – See Appendix F. 30 Day Notice to Prior Authorize Xiaflex®– See Appendix G. Drug Utilization Review of Biologic Products for the Treatment of Rheumatoid Arthritis, Crohn’s Disease, Plaque Psoriasis, and Ankylosing Spondylitis – See Appendix H. FDA and DEA Updates – See Appendix I. Future Business Adjournment ORI-4403 • P.O. BOX 26901 • OKLAHOMA CITY, OKLAHOMA 73126-0901 • (405) 271-9039 • FAX: (405) 271-2615 Oklahoma Health Care Authority Drug Utilization Review Board (DUR Board) Meeting – August 10, 2011 @ 6:00 p.m.
    [Show full text]
  • Palm Oil Shopping Guide: Current Best Choices
    FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of Make a Difference RSPO Members RSPO Members RSPO Members RSPO Members RSPO Members for Wild 3 Musketeers Cinnamon Toast Crunch Honey Maid Grahams Mothers Cookies Splenda Orangutans Act II Coffee Mate Hot Pockets Mountain High Yogurt Starburst Adam's PB Country Crock Hungry Jack Muffin Mam Pastries Stouffers Almond Joy Country Time Hunt's Muir Glen Trident Gum BOYCOTTING PALM Altoids Crisco International Delight Nabisco Sun Chips OIL IS NOT THE Arnott's Biscuits Crunch and Munch Jenny Craig Meals Nature Valley SuperMoist Cake Mixes SOLUTION… Aunt Jemima Foods Dean's Dips Jeno's Pizza Near East Sweet Rewards Bars Austin Brand Crackers Doritos Jif PB Nerds Sweet Tarts Supporting Baby Ruth Dove Chocolates Jiffy Pop Nesquik Swiss Miss companies that are Bac Os Dreyer's Jolly Ranchers Nestle Products Tombstone Pizza members of the Baker's Chocolate Edy's Justin's NutButter Nutter Butter Cookies Tostitos RSPO (Roundtable on Balance Bars Egg Beaters Justin's PB Cups Old El Paso Total Cereal Sustainable Palm Oil) Banquet Meals Endangered Species Choc. Keebler Cookies Oreo Cookies Totino's Pizza is the most Barilla Famous Amos Cookies Keebler Crackers Orville Redenbacher's Trix Cereal responsible solution. BelVita Fiber One Products Kellogg's Products Pam Tuna Helper Ben & Jerry's Ice Cream Fleischmann's Kid Cuisine Parent's Choice Twix Bertolli Frito Lay Kit Kat Parkay Twizzlers For more information Betty Crocker products Folgers Kix Cereal Pasta
    [Show full text]
  • Case 10 Raisio Group and the Benecol Launch*
    CTAC10 4/13/07 17:24 Page 163 case 10 Raisio Group and the Benecol Launch* Case [A]: The Situation in January 1997 During 1996, Raisio Group, a 57-year-old grain-milling company based in Raisio in the south-west of Finland, emerged from obscurity to become the second most valuable public company in Finland (after Nokia) and the focus of worldwide attention. The launch of Benecol, its cholesterol-lowering margarine, at the end of 1995 had attracted the interest of food processors and supermarket groups throughout the world and fueled a surge of investor interest. Demand for the product had outstripped Raisio’s capability to produce the active ingredient in Benecol, stanol ester. On the Helsinki stock market, foreign demand pushed Raisio’s share price from FIM61 at the beginning of the year to FIM288 at the end (after touching FIM322 during the summer).1 CEO Matti Salminen commented: 1996 will go down in the Raisio Group’s history as the “Benecol year” – such was the role of this new cholesterol-reducing margarine in increasing the Group’s visibility and raising its profile in all our sectors of operations. Although we have not been able to meet even the domestic demand for Benecol margarine so far, the product is already known worldwide and great expectations are attached to it. The Benecol phenomenon quintupled the value of our shares, increasing the Group’s capitalization by billions of Finnish marks.2 It was the international prospects for Benecol margarine (and potentially other food products incorporating stanol ester) that had drawn a bevy of stock analysts * This case draws upon an earlier case by Michael H.
    [Show full text]